Elamipretide vs MOTS-c
Two mitochondria-targeted peptides at opposite ends of the evidence: elamipretide (Forzinity) was FDA-approved in September 2025 for Barth syndrome, while MOTS-c has no completed human efficacy trial and only an advisory committee vote (July 2026) behind it.
Elamipretide (SS-31, mitochondrial-targeted peptide)
An investigational mitochondria-targeting peptide studied for rare mitochondrial disease and age-related organ decline.
Mitochondrial ORF of the 12S rRNA type-c
A mitochondrial-derived peptide studied as an exercise mimetic that improves metabolic homeostasis and insulin sensitivity in animal models.
| Attribute | Elamipretide | MOTS-c |
|---|---|---|
| Category | Anti-aging | Longevity |
| FDA status | FDA-approved September 19, 2025 as Forzinity (accelerated approval) for Barth syndrome; other uses investigational | Not FDA-approved. PCAC voted 7 to 5 to recommend for compounding (July 2026); awaiting FDA rulemaking; one Phase 2a trial recruiting |
| Half-life | ~2-3 hours | Short |
| Molecular weight | 639.8 Da | ~2,174 Da |
| Mechanism | Binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and improving electron transport efficiency and ATP production. | Translocates to the nucleus under metabolic stress and activates AMPK-related pathways that regulate glucose and lipid metabolism. |
| Legal status (US) | FDA-approved (Forzinity, Barth syndrome only), prescription only; other uses investigational | Not approved; research use only |
Frequently asked questions
What is the difference between Elamipretide and MOTS-c?
Elamipretide: An investigational mitochondria-targeting peptide studied for rare mitochondrial disease and age-related organ decline. MOTS-c: A mitochondrial-derived peptide studied as an exercise mimetic that improves metabolic homeostasis and insulin sensitivity in animal models.
Which has stronger research evidence, Elamipretide or MOTS-c?
Elamipretide is rated Moderate and MOTS-c is rated Preliminary for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are Elamipretide and MOTS-c FDA-approved?
Elamipretide: FDA-approved September 19, 2025 as Forzinity (accelerated approval) for Barth syndrome; other uses investigational. MOTS-c: Not FDA-approved. PCAC voted 7 to 5 to recommend for compounding (July 2026); awaiting FDA rulemaking; one Phase 2a trial recruiting.
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.